Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

During the three years ended December 31, 2015, the Company recognized the following revenues attributable to the Janssen HCV collaboration:



	2015		2014		2013
	(in thousands)
Royalty revenues	$	1,518	$	13,481	$	130,724
Collaborative revenues:
Up-front and amendment payments revenues	$	—	$	—	$	190,345
Net reimbursement for telaprevir development costs	1,946		7,104		2,793
Reimbursement for manufacturing services	—		—		10,299
Total collaborative revenues attributable to the Janssen HCV collaboration	$	1,946	$	7,104	$	203,437
Total revenues attributable to the Janssen HCV collaboration	$	3,464	$	20,585	$	334,161

Fair Value of Consideration Transferred

The consideration paid and the fair value of the contingent milestone and royalty payments payable by the Company pursuant to the Parion Agreement are set forth in the table below:



	June 4, 2015
	(in thousands)
Up-front payment	$	80,000
Fair value of contingent milestone and royalty payments	175,340
Total	$	255,340

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The following table summarizes the fair values of the assets and liabilities recorded on the effective date of the Parion Agreement:



	June 4, 2015
	(in thousands)
Intangible assets	$	255,340
Goodwill	10,468
Deferred tax liability	(91,023		)
Net other assets (liabilities)	(10,468		)
Net assets attributable to noncontrolling interests	$	164,317

Schedule of Collaborative Arrangement Activity Net Loss Attributable to Noncontrolling Interest

An aggregate summary of net loss attributable to noncontrolling interest related to the Company’s VIEs for the three years ended December 31, 2015 was as follows:



	2015			2014			2013
	(in thousands)
Loss attributable to noncontrolling interest before provision for income taxes	$	6,646		$	764		$	283,747
Provision for (benefit from) income taxes	29,731			3,876			(166,145		)
(Increase) decrease in fair value of contingent milestone and royalty payments	(4,530		)	(450		)	124,920
Net loss attributable to noncontrolling interest	$	31,847		$	4,190		$	242,522

Schedule of Collaborative Arrangement Summary Of Items Related To Variable Interest Entities

The following table summarizes items related to the Company’s VIEs included in the Company’s consolidated balance sheets as of the dates set forth in the table:



	December 31, 2015		December 31, 2014
	(in thousands)
Restricted cash and cash equivalents (VIE)	$	78,910	$	8,418
Prepaid expenses and other current assets	3,138		268
Intangible assets	284,340		29,000
Goodwill	19,391		8,923
Other assets	455		42
Accounts payable	676		189
Taxes payable	24,554		3,594
Other current liabilities	7,100		297
Deferred tax liability, net	110,438		11,544
Other liabilities	300		300
Noncontrolling interest	153,661		21,177